Ratings by Stephens (Sudan Loganathan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/12/2026 | Palvella Therapeutics | PVLA | New Coverage | Overweight (N/A) |
121.29 (157.24) |
29.64% | Details | |
| 5/7/2026 | Catalyst Pharmaceutical Partners | CPRX | Downgrade | Equal Weight (Overweight) |
30.52 (31.49) |
3.18% | Details | |
| 3/31/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Equal Weight (Overweight) |
27.58 (40.50) |
46.85% | Details | |
| 3/2/2026 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Apogee Therapeutics Inc | APGE | New Coverage | Overweight (N/A) |
76.81 (134.00) |
74.46% | Details | |
| 12/11/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2025 | Delcath Systems | DCTH | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2025 | Centessa Pharmaceuticals | CNTA | New Coverage | Overweight (N/A) |
24.15 (27.58) |
14.2% | Details | |
| 10/28/2025 | Candel Therapeutics Inc. | CADL | New Coverage | Overweight (N/A) |
5.40 (10.18) |
88.52% | Details | |
| 9/18/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2025 | C4 Therapeutics | CCCC | Upgrade | Overweight (Equal Weight) |
2.66 (3.69) |
38.72% | Details | |
| 6/30/2025 | Sensei Biotherapeutics | SNSE | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2025 | Exelixis | EXEL | Upgrade | Overweight (Equal Weight) |
43.37 (55.92) |
28.94% | Details | |
| 6/3/2025 | Blueprint Medicines | BPMC | Downgrade | Equal Weight (Overweight) |
127.79 (129.46) |
1.31% | Details | |
| 4/9/2025 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/24/2025 | Elevation Oncology | ELEV | Downgrade | Equal Weight (Overweight) |
0.30 (0.37) |
23.33% | Details | |
| 2/28/2025 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2025 | ADC Therapeutics | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/27/2024 | Exelixis | EXEL | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 11/19/2024 | Actinium Pharma | ATNM | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/18/2024 | Catalyst Pharmaceutical Partners | CPRX | New Coverage | Overweight (N/A) |
20.60 (30.52) |
48.16% | Details | |
| 11/18/2024 | Kymera Therapeutics | KYMR | New Coverage | Overweight (N/A) |
41.96 (115.77) |
175.91% | Details | |
| 11/18/2024 | C4 Therapeutics | CCCC | New Coverage | Equal Weight (N/A) |
4.31 (2.66) |
-38.28% | Details | |
| 11/18/2024 | Arvinas Inc. | ARVN | New Coverage | Overweight (N/A) |
22.48 (8.01) |
-64.37% | Details | |
| 11/18/2024 | Ideaya Biosciences | IDYA | New Coverage | Overweight (N/A) |
26.64 (36.01) |
35.17% | Details | |
| 11/8/2024 | ADC Therapeutics | ADCT | New Coverage | Overweight (N/A) |
3.20 (1.35) |
-57.81% | Details | |
| 10/30/2024 | Exelixis | EXEL | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/14/2024 | Exelixis | exel | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/14/2024 | Elevation Oncology | ELEV | New Coverage | Overweight (N/A) |
3.28 (0.37) |
-88.72% | Details | |
| 5/14/2024 | Inovio Pharmaceuticals | INO | New Coverage | Overweight (N/A) |
10.65 (1.12) |
-89.48% | Details | |
| 5/14/2024 | Blueprint Medicines | BPMC | New Coverage | Overweight (N/A) |
106.70 (129.46) |
21.33% | Details | |
| 5/14/2024 | Exelixis | EXEL | New Coverage | Overweight (N/A) |
21.37 (55.92) |
161.68% | Details | |
| 5/14/2024 | Nurix | NRIX | New Coverage | Overweight (N/A) |
13.51 (23.12) |
71.13% | Details | |
| 5/14/2024 | Sensei Biotherapeutics | SNSE | New Coverage | Overweight (N/A) |
1.51 (13.85) |
817.22% | Details | |
| 5/14/2024 | Actinium Pharma | ATNM | New Coverage | Overweight (N/A) |
8.73 (0.92) |
-89.46% | Details | |
| 5/14/2024 | Delcath Systems | DCTH | New Coverage | Overweight (N/A) |
5.71 (12.81) |
124.34% | Details |
